Replies to post #347847 on Amarin Corp Plc (AMRN)

[oneragman]

raf, not impressed. KM better have a real plan. I know a lot of you think this is cheap here and it is. Doesn't mean they can't screw this up and things get worse.

[zmanindc]

Thanks RAF…… the problem is not generics, this is a marketing and image issue as doctors think this is a Trig lowering drug and the reason we see steady GL and rising GV. They have not educated the doctors this is for CVD prevention. Pfizer could double sales in 30 days.

[rosemountbomber]

Thank you Raf. Appreciate you taking the time and effort.

[Anilkhera]

Thanks Rafunrafun!!

[ralphey]

Apparently supply is still not an issue - Thero boasted he could out sell supply - doesn't look that way as their marketing is absolutely dismal

Dual issue: a.) Infringement b.) Marketing

End Result - Poor sales Poor revenues poor stock price

[johngnatt]

What database can be used to identify what % of generic prescription is used for Cvd. vs TG?

[rafunrafun]

Scripts for week ending July 23, 2021

Overall drug TRx are -0.5% w/w

Vascepa
TRx 85,070; -0.3% (-234) w/w; -2.3% y/y
NRx 37,910; -0.3% (-108) w/w; -5.7% y/y
Ref 47,160; -0.3% (-126) w/w; +0.6% y/y

Lovaza (Generic & Brand)
TRx 63,219; -0.4% (-247) w/w; +4.9% y/y
NRx 30,998; -0.8% (-240) w/w; +4.0% y/y
Ref 32,221; -0.0% (-7) w/w; +5.9% y/y

Generic Vascepa
TRx 15,623; +8.8% (+1,267) w/w; As % of total V: 15.5%
NRx 9,038; +11.3% (+916) w/w; As % of total V: 19.3%
Ref 6,585; +5.6% (+351) w/w; As % of total V: 12.3%

Generic Vascepa by Manufacturer
Hikma TRx 12,075; Generic share 77.3%; Total V share 12.0%
Reddy TRx 3,548; Generic share 22.7%; Total V share 3.5%